Bengal Physician Journal

Register      Login

VOLUME 8 , ISSUE 1 ( January-April, 2021 ) > List of Articles

LETTER TO THE EDITOR

In Reference to “Optimizing Non-cardiac Prescription in a Cardiac Patient”

Sandip Ghosh

Citation Information : Ghosh S. In Reference to “Optimizing Non-cardiac Prescription in a Cardiac Patient”. Bengal Physician Journal 2021; 8 (1):30-31.

DOI: 10.5005/jp-journals-10070-7047

License: CC BY-NC 4.0

Published Online: 17-08-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Abstract


  1. AFFIR Ming what we know about IV iron in patients with acute heart failure. American College of Cardiology. 2021. Available at: http://www.acc.org%2flatest-in-cardiology%2farticles%2f2021%2f03% 2f03%2f17%2f59%2faffirming-what-we-know-about-iv-iron-in-patients-with-acute-heart-failure
  2. Tersalvi G, Biasco L, Cioffi GM, et al. Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective. J Clin Med 2020;9:7. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408729/
  3. Collet J-P, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42(14):1289–1367. DOI: 10.1093/eurheartj/ehaa575.
  4. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381(21):2032–2042. DOI: 10.1056/NEJMoa1908419.
  5. ACE Inhibitors: how to start – edren.org. 2021. Available at: https://edren.org/ren/handbook/unithdbk/prescribing/ace-inhibitors-how-to-start/
  6. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383(23):2219–2229. DOI: 10.1056/NEJMoa2025845.
  7. de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2020;98(4):S1–S115. DOI: 10.1016/j.kint.2020.06.019.
  8. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486.
  9. Mahajan S, Mahajan AU. Current clinical evidence of trimetazidine in the management of heart disease in patients with diabetes. J Assoc Physicians India 2020;68(11):46–50. Available at: https://pubmed.ncbi.nlm.nih.gov/33187037/
  10. Shaw JA, Cooper ME. Contemporary management of heart failure in patients with diabetes. Diabetes Care 2020;43(12):2895–2903. DOI: 10.2337/dc20-2173.
  11. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 2019;140(7):e294–e324. DOI: 10.1161/CIR.0000000000000691.
  12. Teo YH, Teo YN, Syn NL, et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc 2021;10(5):e019463. Available at: https://www.ahajournals.org/doi/abs/10.1161/JAHA.120.019463
  13. Honigberg MC, Chang L-S, McGuire DK, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiol 2020;5(10):1182–1190. DOI: 10.1001/jamacardio.2020.1966.
  14. New methodologies for the treatment of refractory angina. American College of Cardiology. 2021. Available at: http.www.acc.org%2flatest-in-cardiology%2farticles%2f2015%2f10%2f07%2f11%2f47%2f new-methodologies-for-the-treatment-of-refractory-angina
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.